NYSE: BLCO
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company with a nearly two-century history. The company operates across three segments: Vision Care (contact lenses and over-the-counter eye care products including dry eye treatments), Surgical (intraocular lenses and other surgical devices for cataract and other ophthalmic procedures), and Pharmaceuticals (branded and international prescription ophthalmic drugs). Key brands include MIEBO and XIIDRA in dry eye treatment, Biotrue ONEday and ULTRA contact lenses, the Blink eye care franchise, and the enVista IOL platform. The company is currently majority-owned by Bausch Health Companies Inc., with an ongoing process toward full separation as an independent publicly traded entity. Bausch + Lomb serves patients and eye care professionals globally through its portfolio of contact lenses, prescription products, over-the-counter options, and surgical devices. Updated
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets. Healthcare keeps that promise.…
Monday's top analyst upgrades and downgrades included AMC Entertainment, Arch Resources, Bausch + Lomb, Lazard, Lucid, MicroStrategy and Paychex.
Thursday's top analyst upgrades and downgrades included Carvana, FedEx, First Solar, Generac, Nike, PagSeguro Digital, Palantir Technologies, Redfin, Regions Financial, Starbucks, Target and Workday.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company with a nearly two-century history.
24/7 Wall St.'s 12-month price target for BLCO is $18.57, rated Buy. The Wall Street consensus target is $19.39. BLCO price prediction →
